Skip to main content
SpringerLink
Log in

NPY family of peptides in endocrine, breast and prostate tumors

  • Chapter
The NPY Family of Peptides in Immune Disorders, Inflammation, Angiogenesis and Cancer

Part of the book series: Progress in Inflammation Research ((PIR))

Conclusions and perspectives

As mentioned in the present review, in the last several years, it was shown that the receptors of regulatory peptides, and specifically of NPY-related peptides, are not only present in normal human tissue, but are also overexpressed in a large variety of human neoplasms [54], highlighting the diagnostic and therapeutical relevance of their evaluation. Neuropeptide receptors are potential targets for imaging and radiotherapy by radiolabeled peptide hormone analogues [55]. For example, the high level of expression of somatostatin receptors on various tumor cells has already provided the molecular basis for successful use of radiolabeled somatostatin analogues as tumor tracers in nuclear medicine [56]. Similarly, the evaluation of the NPY system with a similar aim may result of clinical utility [36, 44, 57]. In addition to radiolabeled analogues for peptides such as somatostatin, cholecystokinin (CCK), gastrin, bombesin, substance P, and vasoactive intestinal peptide (VIP), analogues for NPY-related peptides have also been introduced [58, 59]. NPY analogues for the Y1-Rs, which are overexpressed in prostate and breast cancer, are currently under development and in different phases of (pre) clinical investigation. Moreover, multireceptor tumor targeting using the combination of bombesin and NPY Y1-R analogues is promising for scintigraphy and peptide receptor radionuclide therapy of breast carcinomas and their lymph node metastases [60].

In conclusion, the current evidence indicates that the NPY-family of peptides may play an important role in the progression of neuroendocrine tumors, and breast and prostate cancer. Future studies will better clarify some aspects of the involvement of these neuropeptides in tumor biology, as well as indicate novel diagnostic markers and therapeutical approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pedrazzini T, Pralong F, Grouzmann E (2003) Neuropeptide Y: the universal soldier. Cell Mol Life Sci 60: 350–377

    Article  PubMed  CAS  Google Scholar 

  2. Magni P (2003) Hormonal control of the neuropeptide Y system. Curr Protein Pept Sci 4: 45–57

    Article  PubMed  CAS  Google Scholar 

  3. Erlinge D, Brunkwall J, Edvinsson L (1994) Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul Pept 50: 259–265

    Article  PubMed  CAS  Google Scholar 

  4. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E et al (1998) Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 83: 187–195

    PubMed  CAS  Google Scholar 

  5. Canto Soler MV, Gallo JE, Dodds RA, Hokfelt T, Villar MJ, Suburo AM (2002) Y1 receptor of neuropeptide Y as a glial marker in proliferative vitreoretinopathy and diseased human retina. Glia 39: 320–324

    PubMed  Google Scholar 

  6. Oben JA, Yang S, Lin H, Ono M, Diehl AM (2003) Norepinephrine and neuropeptide Y promote proliferation and collagen gene expression of hepatic myofibroblastic stellate cells. Biochem Biophys Res Commun 302: 685–690

    Article  PubMed  CAS  Google Scholar 

  7. Hansel DE, Eipper BA, Ronnett GV (2001) Neuropeptide Y functions as a neuroproliferative factor. Nature 410: 940–944

    Article  PubMed  CAS  Google Scholar 

  8. Zukowska Z, Grant DS, Lee EW (2003) Neuropeptide Y: a novel mechanism for ischemic angiogenesis. Trends Cardiovasc Med 13: 86–92

    Article  PubMed  CAS  Google Scholar 

  9. Tatemoto K, Carlquist M, Mutt V (1982) Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 313: 404–406

    Google Scholar 

  10. Yazawa K, Kuroda T, Watanabe H, Shimozawa N, Nimura Y, Nakata S, Fujimori Y, Koide N, Koike S, Kajikawa S et al (1998) Multiple carcinoids of the duodenum accompanied by type I familial multiple endocrine neoplasia. Surg Today 28: 636–639

    Article  PubMed  CAS  Google Scholar 

  11. Gurevich L, Kazantseva I, Isakov VA, Korsakova N, Egorov A, Kubishkin V, Bulgakov G (2003) The analysis of immunophenotype of gastrin-producing tumors of the pancreas and gastrointestinal tract. Cancer 98: 1967–1976

    Article  PubMed  Google Scholar 

  12. Chabot JG, Enjalbert A, Pelletier G, Dubois PM, Morel G (1988) Evidence for a direct action of neuropeptide Y in the rat pituitary gland. Neuroendocrinology 47: 511–517

    PubMed  CAS  Google Scholar 

  13. Adams EF, Venetikou MS, Woods CA, Lacoumenta S, Burrin JM (1987) Neuropeptide Y directly inhibits growth hormone secretion by human pituitary somatotropic tumours. Acta Endocrinol (Copenh) 115: 149–154

    CAS  Google Scholar 

  14. Grouzmann E, Deruaz JP, Gomez F, Waeber G (1998) Immunolocalization of neuropeptide Y in human pituitary tumours. Regul Pept 75-76: 89–92

    Article  PubMed  CAS  Google Scholar 

  15. Nakao K, Itoh H, Takaya K (2000) Current topics in pheochromocytoma. Biomed Pharmacother 54 (Suppl 1): 124–128

    Google Scholar 

  16. deS Senanayake, Denker J, Bravo EL, Graham RM (1995) Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest 96: 2503–2509

    CAS  Google Scholar 

  17. Grouzmann E, Werffeli-George P, Fathi M, Burnier M, Waeber B, Waeber G (1994) Angiotensin-II mediates norepinephrine and neuropeptide-Y secretion in a human pheochromocytoma. J Clin Endocrinol Metab 79: 1852–1856

    Article  PubMed  CAS  Google Scholar 

  18. Lundberg JM (1996) Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 48: 113–178

    PubMed  CAS  Google Scholar 

  19. Eurin J, Barthelemy C, Masson F, Soualmia H, Sarfati E, Carayon A (2002) Bradykinininduced neuropeptide Y release by human pheochromocytoma tissue. Neuropeptides 36: 257–262

    Article  PubMed  CAS  Google Scholar 

  20. O’Connor DT, Deftos LJ (1986) Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 314: 1145–1151

    PubMed  CAS  Google Scholar 

  21. Boomsma F, Bhaggoe UM, Man in ’t Veld AJ, Schalekamp MA (1995) Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. Clin Chim Acta 239: 57–63

    Article  PubMed  CAS  Google Scholar 

  22. Tabarin A, Minot AP, Dallochio M, Roger P, Ducassou D (1992) Plasma concentration of neuropeptide Y in patients with adrenal hypertension. Regul Pept 42: 51–61

    Article  PubMed  CAS  Google Scholar 

  23. Senanayake P, Denker J, Bravo EL, Graham RM (1995) Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest 96: 2503–2509

    Article  CAS  Google Scholar 

  24. Liu J, Kahri AI, Heikkila P, Voutilainen R (1999) Regulation of neuropeptide Y mRNA expression in cultured human pheochromocytoma cells. Eur J Endocrinol 141: 431–435

    Article  PubMed  CAS  Google Scholar 

  25. Osamura RY, Tsutsumi Y, Yanaihara N, Imura H, Watanabe K (1987) Immunohistochemical studies for multiple peptide-immunoreactivities and co-localization of Metenkephalin-Arg6-Gly7-Leu8, neuropeptide Y and somatostatin in human adrenal medulla and pheochromocytomas. Peptides 8: 77–87

    Article  PubMed  CAS  Google Scholar 

  26. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA (1989) Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 7: 1720–1725

    PubMed  CAS  Google Scholar 

  27. Eurin J, Barthelemy C, Masson F, Maistre G, Soualmia H, Noe E, Sarfati E, Eurin B, Carayon A (2000) Release of neuropeptide Y and hemodynamic changes during surgical removal of human pheochromocytomas. Regul Pept 86: 95–102

    Article  PubMed  CAS  Google Scholar 

  28. Connell JM, Corder R, Asbury J, Macpherson S, Inglis GC, Lowry P, Burt AD, Semple PF (1987) Neuropeptide Y in multiple endocrine neoplasia: release during surgery for phaeochromocytoma. Clin Endocrinol (Oxf) 26: 75–84

    CAS  Google Scholar 

  29. Korner M, Waser B, Reubi JC (2004) High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia. Clin Cancer Res 10: 8426–8433

    PubMed  Google Scholar 

  30. Kogner P, Bjork O, Theodorsson E (1993) Neuropeptide Y in neuroblastoma: increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Med Pediatr Oncol 21: 317–322

    PubMed  CAS  Google Scholar 

  31. O’Dorisio MS, Hauger M, O’Dorisio TM (2002) Age-dependent levels of plasma neuropeptides in normal children. Regul Pept 109: 189–192

    PubMed  CAS  Google Scholar 

  32. Magni P, Maggi R, Pimpinelli F, Motta M (1998) Cholinergic muscarinic mechanisms regulate neuropeptide Y gene expression via protein kinase C in human neuroblastoma cells. Brain Res 798: 75–82

    Article  PubMed  CAS  Google Scholar 

  33. Magni P, Beretta E, Scaccianoce E, Motta M (2000) Retinoic acid negatively regulates neuropeptide Y expression in human neuroblastoma cells. Neuropharmacology 39: 1627–1635

    Article  Google Scholar 

  34. Magni P, Vettor R, Pagano C, Calcagno A, Martini L, Motta M (2001) Control of the expression of human neuropeptide Y by leptin: in vitro studies. Peptides 22: 415–420

    PubMed  CAS  Google Scholar 

  35. Mannon PJ, Kaiser LM (1997) Retinoic acid is a negative regulator of the neuropeptide Y/peptide YY Y1 receptor gene in SK-N-MC cells. J Neurochem 68: 20–25

    PubMed  CAS  Google Scholar 

  36. Reubi JC, Gugger M, Waser B, Schaer JC (2001) Y1-Mediated effect of neuropeptide Y in cancer: Breast carcinomas as targets. Cancer Res 61: 4636–4641

    PubMed  CAS  Google Scholar 

  37. Finklestein JZ, Krailo MD, Lenarsky C, Ladisch S, Blair J, Reynolds CP, Sitarz AL, Denmann-Hammon G (1992) 13-cis retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from Children’s Cancer Study Group. Med Pediatr Onc 20: 307–311

    CAS  Google Scholar 

  38. Li Q, Johansson H, Grimelius L (1999) Innervation of human adrenal gland and adrenal cortical lesions. Virchows Arch 435: 580–589

    Article  PubMed  CAS  Google Scholar 

  39. Voutilainen R (1998) Adrenocortical cells are the site of secretion and action of insulinlike growth factors and TNF-alpha. Horm Metab Res 30: 432–435

    Article  PubMed  CAS  Google Scholar 

  40. Waeber G, Gomez F, Bishof-Delaloye A, Chaubert P, Francke ML, Haefliger JA, Scherrer U, Centeno G, Temler E, Nicod P (1997) Insulinoma associated with a case of multiple endocrine neoplasia type I: Functional somatostatin receptors and abnormal glucose-induced insulin secretion. Horm Res 48: 76–82

    Article  PubMed  CAS  Google Scholar 

  41. Murakami O, Takahashi K, Sone M, Totsune K, Ohneda M, Itoi K, Yoshinaga K, Mouri T (1993) An ACTH-secreting bronchial carcinoid: presence of corticotropin-releasing hormone, neuropeptide Y and endothelin-1 in the tumor tissue. Acta Endocrinol (Copenh) 128: 192–196

    CAS  Google Scholar 

  42. Murakami O, Takahashi K, Satoh F, Totsune K, Sone M, Arihara Z, Andoh N, Mouri T (1998) Expression of adrenomedullin and adrenomedullin mRNA in ectopic ACTHsecreting tumors. Eur J Endocrinol 138: 436–439

    Article  PubMed  CAS  Google Scholar 

  43. Jansson JO, Svensson J, Bangtsson BA, Frohman LA, Ahlman H, Wangberg B, Nilsson O, Nilsson M (1998) Acromegaly and Cushing’s syndrome due to ectopic production of GHRH and ACTH by a thymic carcinoid tumour: In vitro responses to GHRH and GHRP-6. Clin Endocrinol 48: 243–250

    CAS  Google Scholar 

  44. Reubi JC, Gugger M, Waser B (2002) Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med 29: 855–862

    Article  CAS  Google Scholar 

  45. de Jong M, Kwekkeboom D, Valkema R, Krenning EP (2003) Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 30: 463–469

    Article  PubMed  CAS  Google Scholar 

  46. Korner M, Waser B, Reubi JC (2004) Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab Invest 84: 71–80

    PubMed  Google Scholar 

  47. Abrahamsson PA (1999) Neuroendocrine cells in tumor growth of the prostate. Endocr Relat Cancer 6: 503–519

    Article  PubMed  CAS  Google Scholar 

  48. Cohen RJ, Glezerson G, Haffejee Z, Afrika D (1990) Prostatic carcinoma: histological and immunohistological factors affecting prognosis. Br J Urol 66: 405–410

    Article  PubMed  CAS  Google Scholar 

  49. Nagakawa O, Ogasawara M, Murata J, Fuse H, Saiki I (2001) Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int J Urol 8: 65–70

    Article  PubMed  CAS  Google Scholar 

  50. Tainio H (1995) Peptidergic innervation of the human prostate, seminal vesicle and vas deferens. Acta Histochem 97: 113–119

    PubMed  CAS  Google Scholar 

  51. Ventura S, Pennefather JN, Mitchelson F (2002) Cholinergic innervation and function in the prostate gland. Pharmacol Ther 94: 93–112

    Article  PubMed  CAS  Google Scholar 

  52. Mack D, Hacker GW, Hauser-Kronberger C, Frick J, Dietze O (1997) Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma. Eur J Cancer 33: 317–318

    Article  PubMed  CAS  Google Scholar 

  53. Magni P, Motta M (2001) Expression of neuropeptide Y receptors in human prostate cancer cells. Ann Oncol 12: S27–S29

    Article  PubMed  Google Scholar 

  54. Reubi JC (1997) Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 41: 63–70

    PubMed  CAS  Google Scholar 

  55. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A et al (2003) Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 30: 417–422

    Article  PubMed  CAS  Google Scholar 

  56. Blum J, Handmaker H, Lister-James J, Rinne N (2000) A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 117: 1232–1238

    Article  PubMed  CAS  Google Scholar 

  57. Reubi JC (2004) Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80(Suppl 1): 51–56

    PubMed  CAS  Google Scholar 

  58. Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B, Valent P et al (1995) Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 36: 1732–1739

    PubMed  CAS  Google Scholar 

  59. Weiner RE, Thakur ML (2002) Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 57: 749–763

    Article  PubMed  CAS  Google Scholar 

  60. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M (2004) Peptide receptor radionuclide therapy. Ann NY Acad Sci 1014: 234–245

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Endocrinologia, via G. Balzaretti 9, 20133, Milano, Italy

    Massimiliano Ruscica, Elena Dozio, Marcella Motta & Paolo Magni

Authors
  1. Massimiliano Ruscica
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Dozio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcella Motta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paolo Magni
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Physiology and Biophysics, Georgetown University Medical Center, 3900 Reservoir Rd., NW, Washington, DC, 20057, USA

    Zofia Zukowska

  2. Wyeth Research, Building A3153 500 Arcola Rd, Collegeville, PA, 19426, USA

    Giora Z. Feuerstein

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Ruscica, M., Dozio, E., Motta, M., Magni, P. (2005). NPY family of peptides in endocrine, breast and prostate tumors. In: Zukowska, Z., Feuerstein, G.Z. (eds) The NPY Family of Peptides in Immune Disorders, Inflammation, Angiogenesis and Cancer. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7427-6_15

Download citation

Publish with us

Policies and ethics

Search

Navigation